TL;DR
This paper introduces a novel 3D-printed PLGA stent loaded with cisplatin (CDDP) for ovarian cancer treatment. This localized drug delivery system demonstrates superior efficacy in reducing tumor growth and apoptosis induction compared to traditional intraperitoneal CDDP injection, while significantly mitigating systemic side effects and potentially overcoming drug resistance.
What Problem Does This Paper Address?
Ovarian cancer (OC) remains a significant challenge due to its high mortality rate and the development of chemotherapy resistance. Cisplatin (CDDP) is a potent chemotherapeutic agent for OC, but its clinical use is hampered by severe adverse side effects and acquired drug resistance. These issues stem from the systemic administration of CDDP, leading to off-target toxicity and the emergence of resistant cancer cells. The paper addresses the critical need for a more effective and safer drug delivery strategy that can enhance CDDP's therapeutic index, reduce side effects, and combat drug resistance.
Methods
The core innovation in this study is the development of a drug-loaded poly (lactic-co-glycolic acid) (PLGA) copolymer stent fabricated using 3D printing technology.
- 3D Printing for Stent Fabrication: This technique allowed for precise control over the stent's structure, including pore size, which is crucial for regulating drug release. The PLGA polymer was combined with CDDP to create a printable solution.
- In Vitro Characterization:
- Physicochemical Properties: Fourier Transform Infrared (FTIR) spectroscopy was used to confirm the presence of CDDP within the PLGA stent. Scanning Electron Microscopy (SEM) was employed to examine the surface morphology and ensure uniform drug distribution without agglomeration.
- Drug Release Kinetics: In vitro drug release studies were conducted over extended periods (up to 30 days) to characterize the sustained release profile of CDDP from the stent.
- Cytotoxicity Assays (CCK8): The efficacy of the CDDP-PLGA stent in inhibiting ovarian cancer cell proliferation was evaluated using CCK8 assays on SKOV3 and A2780 cell lines.
- Apoptosis Assays (Flow Cytometry): The ability of the CDDP-PLGA stent to induce apoptosis in cancer cells was assessed using Annexin V-FITC and propidium iodide staining followed by flow cytometry.
- In Vivo Studies:
- Animal Model: Immunodeficient athymic BALB/c nude mice were used to establish subcutaneous ovarian cancer xenografts.
- Treatment Groups: Mice were treated with saline (control), free CDDP (intraperitoneal injection), or the CDDP-PLGA stent (surgically implanted near the tumor).
- Efficacy Assessment: Tumor growth, body weight changes, and final tumor volume were monitored.
- Molecular Analysis: Immunohistochemistry (IHC), Western Blot (WB), and Real-time PCR (RT-PCR) were used to analyze the expression levels of key proteins and genes related to drug resistance (P-gp), angiogenesis (VEGF), cell proliferation (Ki67, PCNA), and apoptosis (caspase-3) in tumor tissues.
Datasets
Not discussed in the paper. The study utilized established ovarian cancer cell lines (SKOV3 and A2780) and primary antibodies for molecular analysis.
Key Insights and Ideas
- 3D Printing for Precision Drug Delivery: The study highlights the power of 3D printing in creating complex drug delivery systems like stents, allowing for tailored drug release profiles and localized administration. This overcomes limitations of traditional nanoparticle formulations, such as poor drug loading and burst release.
- Sustained Localized Release is Key: The PLGA stent provides a sustained, localized release of CDDP, which is crucial for maintaining therapeutic drug concentrations at the tumor site while minimizing systemic exposure. This approach directly addresses the toxicity and resistance issues associated with conventional CDDP administration.
- Overcoming Drug Resistance Mechanisms: The CDDP-PLGA stent demonstrated a significant reduction in P-glycoprotein (P-gp) expression, a major contributor to multidrug resistance (MDR) in ovarian cancer. This suggests the stent can help reverse or prevent the development of resistance.
- Inhibiting Angiogenesis: The study found that the CDDP-PLGA stent significantly reduced VEGF expression, a key factor in tumor angiogenesis and growth. This dual action of directly killing cancer cells and starving the tumor of its blood supply is a powerful therapeutic strategy.
- Enhanced Apoptosis Induction: The stent effectively promoted apoptosis in cancer cells, as evidenced by increased caspase-3 expression and flow cytometry results, indicating a more potent cell death mechanism compared to free CDDP.
Key Results
- In Vitro Cytotoxicity: The CDDP-PLGA stent significantly inhibited the proliferation of SKOV3 and A2780 ovarian cancer cells, with a more pronounced effect observed over time compared to free CDDP.
- In Vitro Apoptosis: Flow cytometry revealed that the CDDP-PLGA stent significantly promoted apoptosis in OC cells compared to free CDDP.
- In Vivo Tumor Growth Inhibition: In nude mice, the CDDP-PLGA stent significantly reduced tumor volume and weight compared to the saline control and free CDDP groups.
- Reduced Systemic Side Effects: Mice treated with the CDDP-PLGA stent showed minimal weight loss and maintained good physical condition, contrasting sharply with the significant weight decline and poor health observed in the free CDDP group.
- Molecular Markers:
- P-gp: CDDP-PLGA significantly decreased P-gp mRNA and protein levels in tumor tissue.
- VEGF: CDDP-PLGA significantly decreased VEGF mRNA and protein levels.
- Proliferation Markers (Ki67, PCNA): Expression levels of Ki67 and PCNA were decreased in the CDDP-PLGA group.
- Apoptosis Marker (Caspase-3): Expression levels of caspase-3 were increased in the CDDP-PLGA group.
Limitations and Future Work
- Pore Size Optimization: The paper notes that different pore sizes of the stent can lead to different porosities and thus affect the drug release rate. Further optimization of pore size could refine the release profile.
- Clinical Translation: While promising, this study was conducted in vitro and in animal models. Further preclinical and clinical trials are necessary to validate the safety and efficacy of this approach in human patients.
- Long-Term Efficacy and Safety: The long-term effects of the PLGA stent and its degradation products need to be thoroughly investigated.
- Combination Therapies: The authors suggest that this approach could be combined with other therapeutic strategies for enhanced outcomes.
The study provides a strong foundation for the development of localized, sustained-release drug delivery systems for ovarian cancer, offering a promising avenue to improve treatment efficacy and patient quality of life.
Summary updated